Obstructive sleep apnea (OSA) and excess weight often go together. Extra tissue around the neck and upper airway makes it easier for the throat to collapse during sleep, and losing weight is one of the most reliable ways to ease the problem. Until recently, though, the only approved GLP-1 option for sleep apnea was a weekly injection. This week, results from two large trials suggested that a once-daily pill could do a similar job.
Here is what the trials tested, how big the improvements were, where the evidence is still thin, and what it means if you snore, wake up exhausted, or already use CPAP.
What was studied
The pill is orforglipron, which Eli Lilly sells under the brand name Foundayo. It's already approved in the U.S. for chronic weight management. It is not currently approved to treat sleep apnea.
The research program, called ATTAIN-OSA, was made up of two randomized, double-blind, placebo-controlled trials. Together they enrolled 712 adults at 66 sites across four continents. Everyone had moderate-to-severe sleep apnea and a body mass index of 27 or higher. People with diabetes or only mild apnea were excluded.
- Trial 1: 363 people who weren't using CPAP or another positive airway pressure (PAP) device.
- Trial 2: 349 people who already used PAP. They paused it for a week before each sleep test so the researchers could measure the drug's effect alone.
Participants took either the pill or a placebo every day for a year. They had overnight sleep studies at the start, at 24 weeks, and at 52 weeks. The results were presented as late-breaking science at the American Heart Association's Scientific Sessions 2026 in Chicago and published at the same time in JAMA. Lilly funded the program.
The results, in plain numbers
Sleep apnea severity is measured with the apnea-hypopnea index (AHI), which counts how many times per hour breathing stops or becomes shallow. At the start, participants averaged roughly 50 to 58 events an hour, well into the severe range (30 or more).
According to Lilly's summary of the 52-week data:
- Breathing interruptions: In people not using PAP, AHI fell by about 21 events per hour on the pill (about 44%) compared with about 4 on placebo. In PAP users, it fell by about 18 events per hour (about 28%) compared with about 6 on placebo.
- Oxygen dips: Hypoxic burden, a measure of how much and how long blood oxygen drops during apnea events, fell by about 56% and 46% in the two trials, compared with about 17–18% on placebo.
- Weight: Participants on the pill lost about 11% of their body weight (roughly 28 pounds), compared with 1–2% on placebo.
- Remission or mild apnea: By the end of the year, 31.5% of non-PAP participants and 19.6% of PAP users on the pill were in remission or down to mild sleep apnea.
The AHA's summary added two cardiovascular signals. Systolic blood pressure dropped by about 7 to 7.5 mm Hg on the pill compared with about 2 mm Hg on placebo, and hs-CRP, a blood marker of inflammation, fell substantially more with the drug. Participants also reported sleeping better.
Wondering whether your sleep is as restful as it should be?
Loud snoring, gasping awake, and heavy daytime sleepiness can all be signs of a breathing problem during sleep. Our free Sleep Score Tool rates your sleep habits and symptoms and suggests practical next steps, including when it makes sense to ask a doctor about a sleep study.
How to read these results
This is strong evidence by sleep-research standards: two large, randomized, placebo-controlled trials lasting a full year. Still, a few points matter when you put the numbers in context.
Most people improved, but most weren't cured. A drop of 20 events an hour is meaningful. But when you start at 50, it usually means moving from severe apnea to moderate apnea, not to normal breathing. That's why the researchers stressed that the drug "is not meant to replace CPAP therapy." They see it as something that could be used alongside CPAP, or for people who can't or won't use a machine. CPAP and other PAP devices remain the first-line treatment.
Weight loss is probably doing most of the work. The researchers believe weight loss drove much of the benefit, though they say future studies need to check whether GLP-1 drugs help the airway in other ways too. In practice, that means the drug is aimed at sleep apnea that's linked to excess weight. It's unlikely to help someone whose apnea comes mainly from jaw structure, large tonsils, or other anatomical causes.
Side effects are common. As with other GLP-1 drugs, the main problems were gastrointestinal: nausea, diarrhea, constipation, indigestion, and vomiting. Most were mild to moderate. Even so, about 7% to 12% of people on the pill stopped because of side effects, compared with 1% to 4% on placebo.
We don't yet know the long-term picture. The trials lasted one year, so they couldn't show whether the drug reduces heart attacks, strokes, or deaths. People with diabetes and mild apnea weren't included, and some racial and ethnic groups were underrepresented.
Pill vs. injection: why the format matters
Tirzepatide (Zepbound), Lilly's injectable GLP-1-based drug, is already FDA-approved for moderate-to-severe sleep apnea in adults with obesity. These new results don't show the pill is better. The trials compared it with placebo, not with the injection. The main difference is convenience. Some people would rather take a daily pill than give themselves a weekly shot, and oral drugs can be easier to manufacture and ship at scale. Lilly says it plans to ask the FDA to approve orforglipron for sleep apnea by the end of 2026, so any approval for this use is still some time away.
A related finding: weight after apnea treatment
A separate, much earlier-stage study published the same week adds a twist. Researchers at Ben-Gurion University of the Negev and Soroka University Medical Center in Israel reported in Scientific Reports that in mice, surgically relieving a chronic airway obstruction was followed by more eating and an average 15% weight gain. Their explanation is that the body's "fight-or-flight" system, which works harder during obstructed breathing, doesn't immediately settle down once breathing returns to normal. As co-lead researcher Ariel Tarasiuk put it, "When the obstruction is removed, these mechanisms do not immediately turn off."
Mouse studies don't translate directly to people, so treat this as a hypothesis, not a warning. It does fit something many clinicians see: treating apnea doesn't automatically bring weight down, and some patients gain weight after starting CPAP. Together, the two studies suggest that sleep apnea care works best when breathing and weight are managed together.
What to do with this news
- If you suspect sleep apnea, get tested first. Loud snoring, pauses in breathing that someone else notices, morning headaches, and constant daytime sleepiness are all reasons to ask about a home or in-lab sleep study. Our guide to sleep apnea symptoms covers the warning signs, and newer smartwatch screening features may help flag a problem, though they can't diagnose it.
- If you use CPAP, don't stop. Nothing in these trials suggests a pill can replace PAP therapy for most people. If you find your machine hard to tolerate, talk to your sleep doctor about mask fit, pressure settings, or other options. Our CPAP guide has practical tips.
- If weight is part of the picture, ask about the full set of options. Approved weight-loss medications, nutrition support, and exercise can all reduce apnea severity. Our overview of natural approaches to sleep apnea and our explainer on sleep and weight loss explain how sleep and weight affect each other.
- Re-test after big changes. If you lose a lot of weight, by any method, ask whether you need a follow-up sleep study. Your apnea severity, and your CPAP pressure needs, may change.
Key takeaways
- Two year-long, randomized trials in 712 adults with overweight or obesity and moderate-to-severe sleep apnea tested orforglipron, a daily GLP-1 pill, against placebo.
- Breathing interruptions fell by about 18 to 21 events an hour on the pill versus about 4 to 6 on placebo. Oxygen dips, blood pressure, and inflammation also improved, and participants lost about 11% of their body weight.
- About 20% to 32% of participants on the pill reached remission or mild apnea. Most still had apnea that needed treatment.
- Gastrointestinal side effects were common, and the pill isn't approved for sleep apnea yet. Lilly plans to file with the FDA by the end of 2026.
- Researchers stress it's meant to work alongside CPAP, not replace it.
For the millions of people whose sleep apnea is tied to their weight, a pill that can meaningfully reduce breathing interruptions would be a useful new option. It won't make CPAP obsolete. But it makes it more realistic to treat the airway and the weight together.
Sources: Medical Xpress (provided by the American Heart Association) — "Daily, oral GLP-1 medication reduced episodes of sleep apnea in adults with excess weight," November 10, 2026, https://medicalxpress.com/news/2026-11-daily-oral-glp-medication-episodes.html. Additional trial figures from Eli Lilly and Company's November 9, 2026 news release, https://investor.lilly.com/node/55271. Mouse study: Medical Xpress (provided by Ben-Gurion University of the Negev) — "Successful sleep apnea treatment may lead to unexpected weight gain," November 10, 2026, https://medicalxpress.com/news/2026-11-successful-apnea-treatment-unexpected-weight.html; Nujedat H et al., Scientific Reports (2026), doi:10.1038/s41598-026-68370-4.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Don't stop or change CPAP therapy or start any medication without talking to your doctor. If you think you may have sleep apnea, ask a healthcare professional about a sleep evaluation.
About Better Night Sleep: Better Night Sleep is an independent sleep-education and product-research resource. Our articles are written and edited by the Better Night Sleep editorial team using reputable public sources and established sleep-health recommendations. Learn more about us.